The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
198
IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
Vienna, Austria
Zentrum für Reisemedizin, Dependance für klinische Studien
Vienna, Austria
Berliner Zentrum Reise- und Tropenmedizin
Berlin, Germany
Seroconversion Rate
Time frame: at Month 12 after booster
Safety and Adverse Events
Time frame: up to Month 12 after booster
Seroconversion
Time frame: at D28 and Month 6 after booster
Geometric Mean Titer
Time frame: D28, Month 6 and Month 12 after booster
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.